Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome
Dec122018

Anavex Life Sciences Reports Fiscal Year 2018 Financial Results And Provides Clinical Study Update

December 12, 2018
Dec102018

Anavex Life Sciences to Announce 2018 Fiscal Year End Financial Results on Wednesday, December 12, 2018

December 10, 2018
Nov82018

Anavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of Parkinson’s Disease Dementia (PDD)

November 8, 2018
Oct302018

First Patient Enrolled in Anavex Life Sciences Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia (PDD)

October 30, 2018
Oct262018

Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

October 26, 2018
Oct192018

Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome

October 19, 2018
Sep262018

Anavex Life Sciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

September 26, 2018
Aug282018

First Patient Enrolled in Anavex Life Sciences Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease

August 28, 2018
Aug92018

Anavex Life Sciences Reports Fiscal Third Quarter 2018 Financial Results

August 9, 2018
Aug72018

Anavex Life Sciences to Announce Fiscal Third Quarter 2018 Financial Results on Thursday, August 9, 2018

August 7, 2018
Jul252018

Anavex Life Sciences Presents New Data Identifying Treatment Response Biomarkers in Alzheimer’s Disease Patients Treated with Investigational ANAVEX®2-73 at 2018 Alzheimer’s Association International Conference (AAIC)

July 25, 2018
Jul92018

Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia

July 9, 2018
1
234
…56789…
101112131415161718192021222324252627282930313233343536373839404142
43

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top